Dynamic Cell Therapies, Inc. is pioneering a novel approach to CAR T cell therapy by developing controllable CAR T cells designed to target difficult-to-treat cancers, including both hematological malignancies and solid tumors. Their platform technology allows for the dynamic control of engineered T cells by uncoupling tumor targeting from CAR T cell activation. This is achieved through the use of an inert small molecule that is conjugated to a tumor-specific antibody. By adjusting the dosage of this small molecule-antibody conjugate, physicians can modulate CAR T cell activity, enhancing the immune response against tumor cells while minimizing the risk of severe side effects.

The controllable CAR T cell system is characterized by its safety, specificity, and effectiveness. The CAR T cells are designed to recognize small molecules, which prevents them from interacting with normal tissues, thereby reducing off-target effects. The system allows for the selective targeting of tumor antigens, and if tumor cells evade recognition, new small molecule-antibody conjugates can be introduced without the need for additional leukapheresis. Furthermore, the technology supports multiplexing, enabling the simultaneous use of multiple antibodies targeting different tumor antigens, which can optimize therapeutic efficacy while limiting toxicity. This innovative approach positions Dynamic Cell Therapies at the forefront of cancer immunotherapy.

United States

Dynamic Cell Therapies is developing controllable CAR T cells to address difficult-to-treat cancers. Our platform technology of dynamic control of engineered T cells will improve the safety, efficacy, and durability of CAR T cell therapies. This system will have immediate applications in hematological cancers, with future approaches in solid tumors and autoimmune diseases.

Dynamic Cell Therapies, Inc.

Company Details